Elena A. Swingler, Wes M. Johnson, Sarah E. Moore, Matthew Song, Jamison Montes de Oca, Clover N. Truong, Ashley M. Wilde, Julio A. Ramirez
{"title":"Antimicrobial IV to PO switch practices at 9 institutions in Kentucky with Established Antimicrobial Stewardship Programs","authors":"Elena A. Swingler, Wes M. Johnson, Sarah E. Moore, Matthew Song, Jamison Montes de Oca, Clover N. Truong, Ashley M. Wilde, Julio A. Ramirez","doi":"10.59541/001c.89676","DOIUrl":null,"url":null,"abstract":"Intravenous (IV) to oral (PO) transition of antimicrobial therapy is a common antimicrobial stewardship activity. Inpatient institutions seeking to create new IV to PO switch services or enhance existing services may benefit from a review of practices utilized at other institutions. The objective of this review is to summarize IV to PO switch practices utilized by healthcare institutions with established antimicrobial stewardship programs across Kentucky. The Kentucky Antimicrobial Stewardship Innovation Consortium (KASIC) invited pharmacists on the Advisory Board to share current IV to PO switch practices utilized at their institutions. The submitted documents were evaluated in a systematic approach and summarized. Nine of ten institutions represented by the Advisory Board submitted an IV to PO switch practice document for analysis. All institutions utilized pharmacist-driven protocols to allow automatic conversion from IV to PO for select antimicrobials based on specific patient criteria. All protocols included the following antimicrobials eligible for conversion: azithromycin, doxycycline, fluconazole, levofloxacin, linezolid, and metronidazole. Majority of protocols also had inclusion and exclusion criteria based on patient specific factors such as ability to use the enteral route, clinical stability, and infection type. There was variation in the level of restriction placed on conversion eligibility criteria among protocols. IV to PO switch practices for antimicrobials vary across the state of Kentucky. Institutions should tailor protocols based on specific needs, clinical leadership support, and feasibility of implementation.","PeriodicalId":273029,"journal":{"name":"Norton Healthcare Medical Journal","volume":"54 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Norton Healthcare Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59541/001c.89676","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Intravenous (IV) to oral (PO) transition of antimicrobial therapy is a common antimicrobial stewardship activity. Inpatient institutions seeking to create new IV to PO switch services or enhance existing services may benefit from a review of practices utilized at other institutions. The objective of this review is to summarize IV to PO switch practices utilized by healthcare institutions with established antimicrobial stewardship programs across Kentucky. The Kentucky Antimicrobial Stewardship Innovation Consortium (KASIC) invited pharmacists on the Advisory Board to share current IV to PO switch practices utilized at their institutions. The submitted documents were evaluated in a systematic approach and summarized. Nine of ten institutions represented by the Advisory Board submitted an IV to PO switch practice document for analysis. All institutions utilized pharmacist-driven protocols to allow automatic conversion from IV to PO for select antimicrobials based on specific patient criteria. All protocols included the following antimicrobials eligible for conversion: azithromycin, doxycycline, fluconazole, levofloxacin, linezolid, and metronidazole. Majority of protocols also had inclusion and exclusion criteria based on patient specific factors such as ability to use the enteral route, clinical stability, and infection type. There was variation in the level of restriction placed on conversion eligibility criteria among protocols. IV to PO switch practices for antimicrobials vary across the state of Kentucky. Institutions should tailor protocols based on specific needs, clinical leadership support, and feasibility of implementation.
抗菌药物治疗从静脉注射(IV)到口服(PO)的转换是一项常见的抗菌药物管理活动。住院机构若想创建从静脉注射到口服药物的新转换服务或加强现有服务,可参考其他机构的做法。本次审查的目的是总结肯塔基州已建立抗菌药物管理计划的医疗机构将静脉注射转为 PO 治疗的做法。肯塔基州抗菌药物管理创新联合会(KASIC)邀请顾问委员会的药剂师分享其所在机构目前采用的从静脉注射到 PO 转换的做法。我们对提交的文件进行了系统的评估和总结。顾问委员会所代表的 10 家机构中有 9 家提交了从静脉注射到 PO 的转换实践文件以供分析。所有机构都采用了药剂师驱动的方案,允许根据特定患者标准将特定抗菌药物从静脉注射自动转换为 PO。所有方案都包括以下符合转换条件的抗菌药物:阿奇霉素、强力霉素、氟康唑、左氧氟沙星、利奈唑胺和甲硝唑。大多数方案还根据患者的具体因素(如使用肠道途径的能力、临床稳定性和感染类型)制定了纳入和排除标准。不同方案对转换资格标准的限制程度存在差异。肯塔基州各地将抗菌药物从静脉注射转为口服的做法各不相同。医疗机构应根据具体需求、临床领导的支持和实施的可行性来定制协议。